Valproic acid is highly teratogenic. It should not be prescribed for women if there is a possibility of becoming pregnant. | |
Phase | Treatment |
---|---|
Acute mania | Antipsychotics: aripiprazole (15-30 mg/day) Aripiprazole Alone or in Combination for Acute Mania, asenapine (10-20 mg/day), haloperidol (2-15 mg/day), cariprazine (1.5-6 mg/day), quetiapine (300-800 mg/day), olanzapine (5-20 mg/day), risperidone (1-6 mg/day) or ziprasidone (80-120 mg/day) |
Lithium (target concentration 0.80-1.20 mmol/l) | |
Valproic acid* (target concentration 450-900 μmol/l) Valproate in the Treatment of Mania | |
Carbamazepine (400-1 600 mg/day) | |
Mood stabilizers and antipsychotics in combination | |
Electroconvulsive therapy (in selected therapy-resistant or psychotic cases) | |
Depression episode | Lamotrigine (50-200 mg/day) |
Lithium (target concentration 0.80-1.20 mmol/l) | |
Valproic acid* (target concentration 450-600 µmol/l) | |
Olanzapine + fluoxetine 5 + 20 - 10 + 40 mg/day | |
Lurasidone (20-120 mg/day) | |
Cariprazine (1.5 mg/day) | |
Quetiapine (300-600 mg/day) | |
Antidepressants (only in combination with mood stabilizers; discontinued gradually when remission is achieved) | |
Electroconvulsive therapy (ECT) | |
Mixed episode | Treatment as in mania (but specific evidence of efficacy for mixed episodes is absent for haloperidol, quetiapine and lithium) |
Maintenance treatment | Lithium (target concentration 0.60-0.80 mmol/l) |
Carbamazepine (400-1 600 mg/day) | |
Valproic acid* (target concentration 450-900 μmol/l) | |
Lamotrigine (50-400 mg/day; not as monotherapy in type I) | |
Aripiprazole (15-30 mg/day), quetiapine (300-600 mg/day) or olanzapine (5-20 mg/day); depot risperidone (25-50 mg/2 weeks) | |
The above drugs in combination |